Actively Recruiting

Phase Not Applicable
Age: 14Years - 80Years
All Genders
ID06185621

The Effect of 100mg Aspirin on Recurrent Acute Pancreatitis: a Prospective Cohort Study

Led by Air Force Military Medical University, China · Updated on 2023-12-29

23

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to explore the effects of taking 100mg aspirin daily on reducing the recurrence of acute pancreatitis, a condition where patients have two or more episodes of inflammation in the pancreas. Recurrent acute pancreatitis is linked to higher risks of complications, lower quality of life, and increased healthcare costs. Current effective prevention methods exist mainly for biliary and alcoholic causes, but not for other causes such as idiopathic pancreatitis. Participants in the study will receive one 100mg aspirin tablet daily by mouth for two years to assess whether aspirin can reduce the frequency of recurrent acute pancreatitis episodes. This is a prospective cohort study sponsored by the Air Force Military Medical University in China. Aspirin is being studied for its possible role in inhibiting the inflammatory process involved in pancreatitis. During the two-year follow-up, researchers will monitor the time between pancreatitis episodes, the number of episodes, their severity, hospital stay lengths, and rates of chronic pancreatitis and new diabetes onset. They will also track aspirin usage, mortality rates, and any adverse events related to aspirin. Participants will be regularly evaluated to assess these outcomes and ensure safety throughout the study period.

CONDITIONS

Brief Title

The Effect of Aspirin on Recurrent Acute Pancreatitis

Who Can Participate

Age: 14Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with recurrent acute pancreatitis
Not Eligible

You will not qualify if you...

  • Less than 2 episodes of acute pancreatitis in the past year
  • Pancreatitis caused by medical procedures or surgery (iatrogenic pancreatitis)
  • Allergy to non-steroid anti-inflammatory drugs (NSAIDs)
  • Regular use of aspirin or other NSAIDs more than 3 times per week
  • Active or recent (within 3 months) peptic ulcer disease or gastrointestinal bleeding, or history of significant liver or kidney disease
  • Low platelet count (below 100 x 10^9/L) or blood clotting issues (INR >1.5)
  • Presence of biliary stones
  • Recent or planned procedures on the pancreas or gallbladder within 2 years
  • High blood triglycerides (>5.65 mmol/L) without regular lipid-lowering treatment
  • Untreated or planned surgery for primary hyperparathyroidism within 2 years
  • Ongoing heavy alcohol use or withdrawal symptoms
  • Pregnancy or breastfeeding
  • Inability to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 2 years

Participants take 100mg aspirin orally once daily to help prevent recurrent acute pancreatitis.

Regular visits during the 2-year treatment period

Trial Site Locations

Total: 1 location

1

Air Force Military Medical University, China

Xi'an, Shaanxi, China, 710032

Actively Recruiting

Loading map...

Research Team

Y

Yanglin Pan, MD

X

Xiaoyu Kang, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Similar Trials

Using a Cross-sectional Partnership to Improve Prevention an...

Colorectal Cancer

Actively Recruiting

2 locations

Prevention Program for Musculoskeletal Disorders Through Act...

Musculoskeletal Disorders (MSDs)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.

Yasunari Takada, Anjana Bhardwaj, Pravin Potdar...

https://pubmed.ncbi.nlm.nih.gov/15489888